Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation

Pulmonary Pharmacology and Therapeutics

Volumn 34, Issue , 2015, Pages 37-45

  Planaguma A ^a   Domenech T ^a   Pont, M ^a   Calama, E ^a   Garcia Gonzalez V ^a   Lopez R ^a   Auli M ^a   Lopez M ^a   Fonquerna, S ^a   Ramos, I ^a   de Alba, J ^a   Nueda, A ^a   Prats, N ^a   Segarra, V ^a   Miralpeix, M ^a   Lehner, M D ^a,b  

^a R and D Centre ^*  (Spain)

^b Dept Clinical and Scientific Affairs R and D   (Germany)

Author keywords

Chemokine receptor; Chemotaxis; COPD; Lung inflammation; Neutrophils; Severe asthma

Indexed keywords

ANTIINFLAMMATORY AGENT; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CXCL1 CHEMOKINE; DIAMINOCYCLOBUTANDIONE 1; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; NAVARIXIN; THIOPYRIMIDINE 1; UNCLASSIFIED DRUG; [1 (2 BROMOPHENYL) 3 (4 CYANO 1H BENZO[D][1,2,3]TRIAZOL 7 YL)UREA]; 1-(2-BROMOPHENYL)-3-(7-CYANO-3H-BENZOTRIAZOL-4-YL)UREA; 2-HYDROXY-N,N-DIMETHYL-3-(2-((1-(5-METHYLFURAN-2-YL)PROPYL)AMINO)-3,4-DIOXOCYCLOBUT-1-ENYLAMINO)BENZAMIDE; BENZAMIDE DERIVATIVE; CARBANILAMIDE DERIVATIVE; CHEMOKINE RECEPTOR CXCR2; CYCLOBUTANE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TRIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MIGRATION; CHEMICAL STRUCTURE; DEGRANULATION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DUNKIN HARTLEY GUINEA PIG; HUMAN; HUMAN CELL; IN VIVO STUDY; LIPOPOLYSACCHARIDE INDUCED LUNG INFLAMMATION; MALE; MEAN RESIDENCE TIME; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NEUTROPHIL COUNT; NONHUMAN; OPEN READING FRAME; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; STABLE EXPRESSION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; GUINEA PIG; HAMSTER; IMMUNOLOGY; INFLAMMATION; LUNG; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; BENZAMIDES; CELL LINE; CRICETINAE; CYCLOBUTANES; GUINEA PIGS; HUMANS; INFLAMMATION; INTERLEUKIN-8; LIPOPOLYSACCHARIDES; LUNG; MALE; NEUTROPHILS; PHENYLUREA COMPOUNDS; REACTIVE OXYGEN SPECIES; RECEPTORS, INTERLEUKIN-8A; RECEPTORS, INTERLEUKIN-8B; SIGNAL TRANSDUCTION; TRIAZOLES;

EID: 84943231273     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.08.002     Document Type: Article

References (29)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines Update 2014.
2. Holtzman M.J., Byers D.E., Alexander-Brett J., Wang X. The role of airway epithelial cells and innate immune cells in chronic respiratory disease. Nat. Rev. Immunol. 2014, 14:686-698.
3. Stockley R.A. Neutrophils and the pathogenesis of COPD. Chest 2002, 121:151S-155S.
4. Hoenderdos K., Condliffe A. The neutrophil in chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 2013, 48:531-539.
5. Stillie R., Farooq S.M., Gordon J.R., Stadnyk A.W. The functional significance behind expressing two CXCL8 receptor types on PMN. J. Leukoc. Biol. 2009, 86:529-543.
6. Mizgerd J.P. Acute lower respiratory tract infection. N. Engl. J. Med. 2008, 358:716-727.
7. Ahuja S.K., Murphy P.M. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 1996, 271:20545-20550.
8. Gonsiorek W., Fan X., Hesk D., Fossetta J., Qiu H., Jakway J., et al. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist. J. Pharmacol. Exp. Ther. 2007, 322:477-485.
9. Holz O., Khalilieh S., Ludwig-Sengpiel A., Watz H., Stryszak P., Soni P., et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur. Respir. J. 2010, 35:564-570.
10. Lazaar A.L., Sweeney L.E., MacDonald A.J., Alexis N.E., Chen C., Tal-Singer R. SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br. J. Clin. Pharmacol. 2011, 72:282-293.
11. Rennard S.I., Dale D.C., Donohue J.F., Kanniess F., Magnussen H., Sutherland E.R., et al. CXCR2 antagonist MK-7123-A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015 Feb 19, [Epub ahead of print].
12. Nair P., Gaga M., Zervas E., Alagha K., Hargreave F.E., O'Byrne P.M., et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin. Exp. Allergy 2012, 42:1097-1103.
13. Kirsten A.M., Förster K., Radeczky E., Linnhoff A., Balint B., Watz H., et al. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm. Pharmacol. Ther. 2015 Apr, 31:36-41.
14. Wiese D., Schmitz K. Expression of recombinant human interleukin-8 and its purification using a single buffer system. J. Immunol. Methods 2011, 364:77-82.
15. 2+ and actin filament in leukocyte shape change. Pharmacology 2009, 83:131-140.
16. Dwyer M.P., Yu Y., Chao J., Aki C., Chao J., Biju P., et al. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist. J. Med. Chem. 2006, 49:7603-7606.
17. Biju P., Taveras A.G., Dwyer M.P., Yu Y., Chao J., Hipkin R.W., et al. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists. Bioorg Med. Chem. Lett. 2009, 19:1431-1433.
18. Bradley M.E., Bond M.E., Manini J., Brown Z., Charlton S.J. SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br. J. Pharmacol. 2009, 158:328-338.
19. Norman P. Evidence on the identity of the CXCR2 antagonist AZD-5069. Expert Opin. Ther. Pat. 2013, 23:113-117.
20. Catusse J., Faye P., Loillier B., Cremers B., Franck R.M., Luccarini J.M., et al. Cloning and characterization of guinea pig interleukin-8 receptor. Biochem. Pharmacol. 2003, 66:1171-1180.
21. Takahashi M., Jeevan A., Sawant K., McMurrayb D.N., Yoshimura T. Cloning and characterization of guinea pig CXCR1. Mol. Immunol. 2007, 44:878-888.
22. Aul R., Patel S., Summerhill S., Kilty I., Plumb J., Singh D. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2. Int. Immunopharmacol. 2012, 13:225-231.
23. Kaur M., Singh D. Neutrophil chemotaxis caused by COPD alveolar macrophages; the role of CXCL8 and the receptors CXCR1/CXCR2. J. Pharmacol. Exp. Ther. 2013, 347:173-180.
24. Zhao X., Town J.R., Li F., Zhang X., Cockcroft D.W., Gordon J.R. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels. J. Immunol. 2009, 182:3213-3222.
25. Nicholls D.J., Wiley K., Dainty I., MacIntosh F., Phillips C., Gaw A., et al. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J. Pharmacol. Exp. Ther. 2015, 353:340-350.
26. Salchow K., Bond M.E., Evans S.C., Press N.J., Charlton S.J., Hunt P.A., et al. A common intracellular allosteric binding site for antagonists of the CXCR2 receptor. Br. J. Pharmacol. 2010, 159:1429-1439.
27. Nicholls D.J., Tomkinson N.P., Wiley K.E., Brammall A., Bowers L., Grahames C., et al. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2. Mol. Pharmacol. 2008, 74:1193-1202.
28. Chapman R.W., Minnicozzi M., Celly C.S., Phillips J.E., Kung T.T., Hipkin R.W., et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J. Pharmacol. Exp. Ther. 2007, 322:486-493.
29. Seiberling M., Kamtchoua T., Stryszak P., Ma X., Langdon R.B., Khalilieh S. Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist. Int. Immunopharmacol. 2013, 17:178-183.